Menu

Inspra上市了吗?价格多少?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Is a new generation of selective aldosterone antagonist, Inspra can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension. It also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension.

In addition, Inspra has a protective effect on the liver, heart disease, and kidneys without damaging the organs. Inspra can promote urination without losing potassium. Hypertension is the most common chronic disease and the main risk factor for cardiovascular and cerebrovascular diseases. So, is Inspra on the market? How much does it cost?

In 2002, Inspra was approved for sale in the United States. After it was launched in the United States, the price was relatively expensive, and many patients could not afford it for a long time!

According to Medical Companion Travel, a box of Inspra 50mg × 100 tablets from India's Lupine Pharmaceuticals costs about $500. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.

The standard starting dose of Inspra is 25 or 50 mg once daily, with subsequent dose adjustments based on blood pressure response and tolerability. The maintenance dose is 25 to 100 mg, taken in one or two divided doses.

Inspra is well tolerated, and the most common side effects include hyperkalemia and increased serum creatinine.

Hepatotoxicity

Inspra has a small probability of causing an increase in serum aminotransferase levels, but the degree is usually weak and the duration is short. There have been no reported cases of clinically apparent idiosyncratic liver injury caused by Inspra. Due to the structural similarity between Inspra and spironolactone, there may be cross-sensitivity between the two, and Inspra may also cause acute liver injury (a few cases have been reported with spironolactone). 

damage mechanism

Metabolized by the cytochrome P450 system (CYP 3A4) in the liver, liver damage may be caused by metabolic intermediates.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。